L-Carnitine has one of the deepest evidence bases in the OTC supplement space. Discovered in 1905, with its structure confirmed in 1927, it has since accumulated dozens of meta-analyses aggregating hundreds of RCTs. The score of 93 reflects that depth, tempered by the fact that functional outcomes -- exercise performance and cognitive function in healthy adults -- remain inconsistent across trials, even where the mechanism is well-established.
| Dimension | Max | Notes | Score |
|---|---|---|---|
| Study Design | 25 | Multiple large human RCTs across indication areas: body weight and composition (37 RCTs in Askarpour 2020 meta-analysis, 43 RCTs in Talenezhad 2020), glycemic control (37 RCTs), cardiovascular function (17 RCTs in heart failure meta-analysis), lipid profile, exercise recovery, and neurological/psychiatric indications. Full marks. | 25 / 25 |
| Sample Size | 20 | Cumulative human participants across published trials number in the tens of thousands. The Askarpour body weight meta-analysis alone included 2,292 participants across 37 RCTs. The cardiac meta-analysis included 1,625 patients. Easily exceeds the 1,000+ threshold for full marks. | 20 / 20 |
| Replication | 20 | Replicated by independent research groups worldwide across multiple decades and indication areas. Researchers at institutions in the US, Italy, UK, Iran, China, Brazil, and Australia have independently produced RCT data. Meta-analyses routinely include 20+ independent groups. Full marks. | 20 / 20 |
| Journal Impact Factor | 15 | Published in Clinical Nutrition ESPEN (IF ~4), Journal of the International Society of Sports Nutrition (IF ~5), Frontiers in Nutrition (IF ~5), Cochrane Database, and Obesity Reviews (IF ~9). Strong specialty nutrition journals; not top-tier general medicine journals like NEJM or Lancet. Score of 8 reflects this accurately -- strong for the supplement space, not exceptional by the catalog's highest standard. | 8 / 15 |
| Funding Independence | 10 | Predominantly academic and government-funded across the evidence base. Multiple Cochrane reviews and NIH-independent research groups. No dominant commercial sponsor; L-carnitine is a commodity ingredient with no single corporate owner driving the research agenda. Full marks. | 10 / 10 |
| Population Diversity | 5 | Studied across a wide range of populations: overweight and obese adults, elderly and centenarians, athletes, type 2 diabetics, heart failure patients, HIV patients, and people with mitochondrial myopathy. Geographic and demographic breadth is strong. Full marks. | 5 / 5 |
| Researcher h-Index | 5 | Research conducted by established academic researchers in clinical nutrition, cardiology, and exercise science at major institutions worldwide. The field is mature enough that h-Index tracking is straightforward across lead authors. Full marks. | 5 / 5 |
| Total | 100 | 93 / 100 |
L-Carnitine is widely used in fitness and performance communities, typically for fat-loss and exercise recovery purposes. User reports are generally positive for energy during exercise, though community discussion frequently notes that results are inconsistent -- which aligns with the clinical literature, where statistically significant weight effects are modest (approximately 1.2 kg average in meta-analysis). Acetyl-L-Carnitine (ALCAR) is the form most discussed in nootropic communities for cognitive benefits.